(Q36621312)

15 August 2017

Interferon-gamma in the first-line therapy of ovarian cancer: a randomized phase III trial (English)

1 reference

15 August 2017

phase III clinical trial

0 references

1 reference

Windbichler GH

1

1 reference

15 August 2017

Hausmaninger H

2

1 reference

15 August 2017

Stummvoll W

3

1 reference

15 August 2017

Graf AH

4

1 reference

15 August 2017

Kainz C

5

1 reference

15 August 2017

Lahodny J

6

1 reference

15 August 2017

Denison U

7

1 reference

15 August 2017

Müller-Holzner E

8

1 reference

15 August 2017

Marth C

9

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 March 2000

1 reference

British Journal of Cancer

15 August 2017

1 reference

15 August 2017

82

1 reference

15 August 2017

6

1 reference

15 August 2017

1138-1144

1 reference

https://scigraph.springernature.com/pub.10.1054/bjoc.1999.1053

15 August 2017

0 references

cites work

Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363351

Cisplatin resistance is associated with reduced interferon-gamma-sensitivity and increased HER-2 expression in cultured ovarian carcinoma cells

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363351

Cellular responses to interferon-gamma

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363351

Interferon-gamma: biology and role in pathogenesis

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363351

Intraperitoneal recombinant interferon gamma in ovarian cancer patients with residual disease at second-look laparotomy

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363351

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363351

Intraperitoneal recombinant alpha-interferon for "salvage" immunotherapy in stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363351

A phase II study of the efficacy of recombinant interferon gamma in relapsing ovarian adenocarcinoma

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363351

Intraperitoneal recombinant gamma-interferon in patients with recurrent ascitic ovarian carcinoma: modulation of cytotoxicity and cytokine production in tumor-associated effectors and of major histocompatibility antigen expression on tumor cells

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363351

Anti-tumor and immunomodulatory activity of intraperitoneal IFN-gamma in ovarian carcinoma patients with minimal residual tumor after chemotherapy

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363351

Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363351

Interferon-gamma for the treatment of metastatic renal cancer: dose-dependent stimulation and downregulation of beta-2 microglobulin and neopterin responses.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363351

Activation or suppression of the tumoricidal properties of monocytes from cancer patients following treatment with human recombinant gamma-interferon.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363351

A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of cis-diamminedichloroplatinum against human breast and ovarian tumor cell lines

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363351

Interferon-γ is required in activation of macrophages for tumor cytotoxicity

28 June 2018

1 reference

12 December 2020

Direct and indirect effects of human recombinant gamma-interferon on tumor cells in a clonogenic assay

1 reference

12 December 2020

The determination of an immunologically active dose of interferon-gamma in patients with melanoma

1 reference

12 December 2020

A phase I trial of intraperitoneal recombinant gamma-interferon in advanced ovarian carcinoma

1 reference

12 December 2020

Modulation of ovarian carcinoma tumor marker CA-125 by gamma-interferon

1 reference

12 December 2020

Gamma-interferon reduces expression of the protooncogene c-erbB-2 in human ovarian carcinoma cells

1 reference

12 December 2020

Effect of prior cancer chemotherapy on human tumor-specific cytotoxicity in vitro in response to immunopotentiating biologic response modifiers

1 reference

12 December 2020

Antitumor activity of gamma-interferon in ascitic and solid tumor models of human ovarian cancer

1 reference

12 December 2020

Modulation of cisplatin cytotoxicity by human recombinant interferon-gamma in human ovarian cancer cell lines

1 reference

12 December 2020

Different effects of interferons, interleukin-1beta and tumor necrosis factor-alpha in normal (OSE) and malignant human ovarian epithelial cells

1 reference

12 December 2020

Identifiers

DOI

10.1054/BJOC.1999.1053

1 reference

Dimensions Publication ID

15 August 2017

0 references

1 reference

15 August 2017

PubMed publication ID

10735496

1 reference